+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07429266

Global Study Evaluating Sapablursen Safety and Effectiveness in Adults with Polycythemia Vera Using Subcutaneous Treatment

Led by Ono Pharmaceutical Co., Ltd. · Updated on 2026-10-29

250

Participants Needed

38

Research Sites

121 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of sapablursen when added to the current standard of care for treating Polycythemia Vera PV. This Phase 3 trial involves participants who depend on phlebotomy and meet specific diagnostic criteria for PV. The study aims to assess how well sapablursen controls the need for phlebotomy and other health measures in this condition. The study has three parts Part 1a is a 32-week period where participants receive either sapablursen or a placebo in a double-blind manner. In Part 1b, participants receive open-label sapablursen for 124 weeks following the initial phase. There is also a long-term extension phase allowing treatment for up to 156 weeks. Sapablursen and placebo are given by subcutaneous injection. Participants will undergo various assessments, including monitoring of hematocrit levels, number of phlebotomies, and patient-reported symptoms such as fatigue and myelofibrosis symptoms. The main outcome is the percentage of participants who do not need phlebotomy between weeks 20 and 32. Safety and effectiveness are followed throughout the study, which may last up to nearly five years from start to completion.

CONDITIONS

Brief Title

INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

Research Team

C

Clinical Team

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here